Navigation Links
Oral Topical Formulation, ARMS-I, Provides Protection Against Upper Respiratory Infections as well as Reducing Severity and Duration of Cold
Date:2/7/2017

CLEVELAND, Feb. 7, 2017 /PRNewswire/ -- The findings of a randomized proof-of-concept clinical trial demonstrating that the oral spray formulation, ARMS-I, provided protection against upper respiratory tract infections ("URIs") in the enrolled study participants, while reducing the severity and duration of cough and sore throat have just been released.

Funded by ARMS Pharmaceutical, the double-blinded, placebo-controlled trial was conducted by University Hospital's Cleveland Medical Center's Division of Infectious Diseases and Case Western Reserve University. The conclusion of the study states, "ARMS-I is safe and well-tolerated, and it reduces influenza symptoms. This product has the potential to prevent viral upper respiratory tract infections."

Chief Scientific Officer of ARMS Pharmaceutical, Dr. Mahmoud Ghannoum said, "The results confirm that our ARMS-I technology has tremendous potential to lead the next generation of drugs in not only the prevention of many upper respiratory infectious diseases, such as influenza, rhinovirus and respiratory syncytial virus, but in the treatment of them as well." 

ARMS-I is a patented formulation, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, "CPC") and components (glycerin and xanthan gum) that form a barrier on the host mucosa, thus preventing viral contact with the host cells and invasion. 

The U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for a pharmacokinetic trial of its ARMS-I drug, as the company continues to study and develop the use of ARMS-I for its first indication as a potential drug for the prevention of influenza.

"It is an exciting time for the company as we actively begin discussions with potential strategic partners to bring ARMS-I to market, a drug with the potential to help millions of people prevent influenza without the worries of side effects or viral resistance," added Afif Ghannoum, Chief Executive Officer of ARMS Pharmaceutical.

About ARMS Pharmaceutical LLC
ARMS Pharmaceutical LLC, a clinical stage pharmaceutical company, was founded in 2013. The company focuses on the R&D of its ARMS technology platform. ARMS-I is the company's lead drug candidate for the prevention of influenza. Through strategic partnerships, ARMS Pharmaceutical plans to commercialize its ARMS platform for the prevention and treatment of various infectious diseases.

Media Contact:
BLAZE PR / Matt Kovacs
mkovacs@blazepr.com
310-395-5050

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oral-topical-formulation-arms-i-provides-protection-against-upper-respiratory-infections-as-well-as-reducing-severity-and-duration-of-cold-300402975.html


'/>"/>
SOURCE ARMS Pharmaceutical LLC
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
2. Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetriks
3. Encore Vision, Inc. Announces Completion of Target Enrollment in Clinical Study Evaluating Topical EV06 for the Treatment of Presbyopia
4. Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
5. Snapshot of Innovations in R&D Targeting Key Applications of Drug Delivery Technologies - Oral Route, Pulmonary, Topical, Implantable, Injectable, Transdermal & Transmucosal Route Analysis
6. Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology
7. Teligent, Inc. Announces Submission of Two Topical ANDAs
8. Global Topical Drug Delivery Partnering 2010-2015
9. Study Shows Safety of BioPharmX Topical Formulation
10. Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
11. Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2018)... ... 2018 , ... In the world of contract manufacturing, Ion Labs is currently ... has been a game-changing year for Ion Labs . Expansions in the form ... growth. Ion Labs attributes its growth to its responsiveness to customer inquiries, staying in ...
(Date:10/11/2018)... ... October 11, 2018 , ... RevSpring, ... that it has completed the strategic combination of RevSpring and Apex Revenue ... cycle engagement, billing, and payments solutions generating over one billion consumer financial ...
(Date:10/11/2018)... (PRWEB) , ... October 11, 2018 , ... In the ... and Europe in two core families and allowance of six more in USA, China ... at the heart of its MRI safety and security products. , The patents assigned ...
Breaking Medicine Technology:
(Date:10/16/2018)... ... October 16, 2018 , ... Bastyr University is pleased announce ... Health and Medicine’s (AIHM) Visionary Award for his passionate efforts in forging a ... selected as AIHM’s recipient of the Visionary Award due to his tireless effort ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... dicentra Global ... Cannabis Edibles HACCP Certification Program . Canada will become the first G7 country in ... the government of Canada also plans to formally legalize the production and use of ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... First Healthcare Compliance, an attorney experienced in employment law, writes frequently on employment ... publications. Recently, she authored a chapter in the Health Care Compliance Professional's Manual ...
(Date:10/16/2018)... ... ... months of training are over. The race has come and gone. It doesn’t matter if ... through the wringer after the big event. Read on for something healthy hints from the ... to treat the body and mind after a long run: , 1. Don’t sit. Walk ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... founded by patient-survivors, and The Avoca Group, Inc., a life sciences consulting ... process, today announced its mutual collaboration that will make Avoca’s industry research ...
Breaking Medicine News(10 mins):